If left undiagnosed and untreated for a prolonged period, fatty liver disease can progress to more serious conditions, such as cirrhosis and liver cancer.
All over the United States, countless research projects designed to improve outcomes have lost funding or been shut down. Even screening efforts targeting patients in impoverished communities have been impacted by these policies.
The first 250 patients has been enrolled in the CORCINCH-HF U.S. pivotal trial evaluating the AccuCinch Transcatheter Left Ventricular Restoration System in patients with HFrEF.
Gregg Stone, MD, discussing the value of IVUS and OCT over angiography to guide PCI procedures and actually improve outcomes based on a 12,000 patient meta analysis presented at ESC 2023.
NCDR report finds hospitals are seeing improvements but are still struggling to reach pre-COVID treatment thresholds years after pandemic precautions upended longstanding processes.
“Given the dramatic difference in death risk for older adults receiving complex PCI, we suggest that such interventions in this exceptionally vulnerable population should be approached with additional caution," researchers wrote.
The FDA is expected to base its decision in part on the STELLAR clinical trial, which included 163 adult patients treated with subcutaneous sotatercept and 160 patients treated with a placebo.
The popular SGLT2 inhibitor, sold by Boehringer Ingelheim and Eli Lilly and Company under the name Jardiance, has already been approved by the FDA to treat type 2 diabetes and heart failure.
